Activity of Moxifloxacin by Itself and in Combination with Ethambutol, Rifabutin, and Azithromycin In Vitro and In Vivo against Mycobacterium avium
Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit StumbleUpon Twitter current issue AAC About AAC Subscribers Authors Reviewers Advertisers Inquiries from the Press Permissions & Commerc...
Saved in:
| Published in | Antimicrobial Agents and Chemotherapy Vol. 45; no. 1; pp. 217 - 222 |
|---|---|
| Main Authors | , , , , , , |
| Format | Journal Article |
| Language | English |
| Published |
Washington, DC
American Society for Microbiology
01.01.2001
|
| Subjects | |
| Online Access | Get full text |
Cover
Loading…
| Abstract | Classifications
Services
AAC
Citing Articles
Google Scholar
PubMed
Related Content
Social Bookmarking
CiteULike
Delicious
Digg
Facebook
Google+
Mendeley
Reddit
StumbleUpon
Twitter
current issue
AAC
About
AAC
Subscribers
Authors
Reviewers
Advertisers
Inquiries from the Press
Permissions & Commercial Reprints
ASM Journals Public Access Policy
AAC
RSS Feeds
1752 N Street N.W. • Washington DC 20036
202.737.3600 • 202.942.9355 fax • journals@asmusa.org
Print ISSN:
0066-4804
Online ISSN:
1098-6596
Copyright © 2014
by the
American Society for Microbiology.
For an alternate route to
AAC
.asm.org, visit:
AAC
|
|---|---|
| AbstractList | Moxifloxacin activity against Mycobacterium aviumcomplex (MAC) was evaluated in vitro against 25 strains. The MIC was determined to range from 0.125 to 2.0 μg/ml. In addition, U937 macrophage monolayers infected with MAC strain 101 (serovar 1) were treated with moxifloxacin (0.25 to 8 μg/ml) daily, and the number of intracellular bacteria was quantitated after 4 days. Moxifloxacin showed inhibitory activity at 0.5 μg/ml and higher. To assess the activity of moxifloxacin containing regimens in vivo, we infected C57BLbg+/bg+ mice with 3 × 107 MAC strain 101 bacteria intravenously. One week later treatment was begun with the following: (i) moxifloxacin (50 mg/kg/day or 100 mg/kg/day), ethambutol (100 mg/kg/day), or a combination of moxifloxacin and ethambutol; or (ii) moxifloxacin (100 mg/kg/day), azithromycin (200 mg/kg/day), or rifabutin (40 mg/kg/day) as oral monotherapy; or (iii) all permutations of two-drug therapy or all three drugs in combination. All groups contained at least 14 animals, and the control group received the drug vehicle. After 4 weeks, quantitative blood cultures were obtained and the number of bacteria in liver and spleen was quantitated. Moxifloxacin, ethambutol, and azithromycin were active as single agents in liver, spleen, and blood. Rifabutin showed inhibitory activity only in the blood. Two-drug combinations containing azithromycin were no more active than azithromycin alone. Similarly, the three-drug combination was not more active than azithromycin alone in the spleen. Rifabutin did not add to the activity of any other single agent or two-drug combination. Moxifloxacin at both concentrations in combination with ethambutol was significantly more active than each drug alone. Moxifloxacin activity against Mycobacterium avium complex (MAC) was evaluated in vitro against 25 strains. The MIC was determined to range from 0.125 to 2.0 μg/ml. In addition, U937 macrophage monolayers infected with MAC strain 101 (serovar 1) were treated with moxifloxacin (0.25 to 8 μg/ml) daily, and the number of intracellular bacteria was quantitated after 4 days. Moxifloxacin showed inhibitory activity at 0.5 μg/ml and higher. To assess the activity of moxifloxacin containing regimens in vivo, we infected C57BL bg + / bg + mice with 3 × 10 7 MAC strain 101 bacteria intravenously. One week later treatment was begun with the following: (i) moxifloxacin (50 mg/kg/day or 100 mg/kg/day), ethambutol (100 mg/kg/day), or a combination of moxifloxacin and ethambutol; or (ii) moxifloxacin (100 mg/kg/day), azithromycin (200 mg/kg/day), or rifabutin (40 mg/kg/day) as oral monotherapy; or (iii) all permutations of two-drug therapy or all three drugs in combination. All groups contained at least 14 animals, and the control group received the drug vehicle. After 4 weeks, quantitative blood cultures were obtained and the number of bacteria in liver and spleen was quantitated. Moxifloxacin, ethambutol, and azithromycin were active as single agents in liver, spleen, and blood. Rifabutin showed inhibitory activity only in the blood. Two-drug combinations containing azithromycin were no more active than azithromycin alone. Similarly, the three-drug combination was not more active than azithromycin alone in the spleen. Rifabutin did not add to the activity of any other single agent or two-drug combination. Moxifloxacin at both concentrations in combination with ethambutol was significantly more active than each drug alone. ABSTRACT Moxifloxacin activity against Mycobacterium avium complex (MAC) was evaluated in vitro against 25 strains. The MIC was determined to range from 0.125 to 2.0 μg/ml. In addition, U937 macrophage monolayers infected with MAC strain 101 (serovar 1) were treated with moxifloxacin (0.25 to 8 μg/ml) daily, and the number of intracellular bacteria was quantitated after 4 days. Moxifloxacin showed inhibitory activity at 0.5 μg/ml and higher. To assess the activity of moxifloxacin containing regimens in vivo, we infected C57BL bg + / bg + mice with 3 × 10 7 MAC strain 101 bacteria intravenously. One week later treatment was begun with the following: (i) moxifloxacin (50 mg/kg/day or 100 mg/kg/day), ethambutol (100 mg/kg/day), or a combination of moxifloxacin and ethambutol; or (ii) moxifloxacin (100 mg/kg/day), azithromycin (200 mg/kg/day), or rifabutin (40 mg/kg/day) as oral monotherapy; or (iii) all permutations of two-drug therapy or all three drugs in combination. All groups contained at least 14 animals, and the control group received the drug vehicle. After 4 weeks, quantitative blood cultures were obtained and the number of bacteria in liver and spleen was quantitated. Moxifloxacin, ethambutol, and azithromycin were active as single agents in liver, spleen, and blood. Rifabutin showed inhibitory activity only in the blood. Two-drug combinations containing azithromycin were no more active than azithromycin alone. Similarly, the three-drug combination was not more active than azithromycin alone in the spleen. Rifabutin did not add to the activity of any other single agent or two-drug combination. Moxifloxacin at both concentrations in combination with ethambutol was significantly more active than each drug alone. Classifications Services AAC Citing Articles Google Scholar PubMed Related Content Social Bookmarking CiteULike Delicious Digg Facebook Google+ Mendeley Reddit StumbleUpon Twitter current issue AAC About AAC Subscribers Authors Reviewers Advertisers Inquiries from the Press Permissions & Commercial Reprints ASM Journals Public Access Policy AAC RSS Feeds 1752 N Street N.W. • Washington DC 20036 202.737.3600 • 202.942.9355 fax • journals@asmusa.org Print ISSN: 0066-4804 Online ISSN: 1098-6596 Copyright © 2014 by the American Society for Microbiology. For an alternate route to AAC .asm.org, visit: AAC Moxifloxacin activity against Mycobacterium avium complex (MAC) was evaluated in vitro against 25 strains. The MIC was determined to range from 0.125 to 2.0 mu g/ml. In addition, U937 macrophage monolayers infected with MAC strain 101 (serovar 1) were treated with moxifloxacin (0.25 to 8 mu g/ml) daily, and the number of intracellular bacteria was quantitated after 4 days. Moxifloxacin showed inhibitory activity at 0.5 mu g/ml and higher. To assess the activity of moxifloxacin containing regimens in vivo, we infected C57BL bg super(+)/bg super(+) mice with 3 times 10 super(7) MAC strain 101 bacteria intravenously. One week later treatment was begun with the following: (i) moxifloxacin (50 mg/kg/day or 100 mg/kg/day), ethambutol (100 mg/kg/day), or a combination of moxifloxacin and ethambutol; or (ii) moxifloxacin (100 mg/kg/day), azithromycin (200 mg/kg/day), or rifabutin (40 mg/kg/ day) as oral monotherapy; or (iii) all permutations of two-drug therapy or all three drugs in combination. All groups contained at least 14 animals, and the control group received the drug vehicle. After 4 weeks, quantitative blood cultures were obtained and the number of bacteria in liver and spleen was quantitated. Moxifloxacin, ethambutol, and azithromycin were active as single agents in liver, spleen, and blood. Rifabutin showed inhibitory activity only in the blood. Two-drug combinations containing azithromycin were no more active than azithromycin alone. Similarly, the three-drug combination was not more active than azithromycin alone in the spleen. Rifabutin did not add to the activity of any other single agent or two-drug combination. Moxifloxacin at both concentrations in combination with ethambutol was significantly more active than each drug alone. Moxifloxacin activity against Mycobacterium avium complex (MAC) was evaluated in vitro against 25 strains. The MIC was determined to range from 0.125 to 2.0 microg/ml. In addition, U937 macrophage monolayers infected with MAC strain 101 (serovar 1) were treated with moxifloxacin (0.25 to 8 microg/ml) daily, and the number of intracellular bacteria was quantitated after 4 days. Moxifloxacin showed inhibitory activity at 0.5 microg/ml and higher. To assess the activity of moxifloxacin containing regimens in vivo, we infected C57BL bg(+)/bg(+) mice with 3 x 10(7) MAC strain 101 bacteria intravenously. One week later treatment was begun with the following: (i) moxifloxacin (50 mg/kg/day or 100 mg/kg/day), ethambutol (100 mg/kg/day), or a combination of moxifloxacin and ethambutol; or (ii) moxifloxacin (100 mg/kg/day), azithromycin (200 mg/kg/day), or rifabutin (40 mg/kg/day) as oral monotherapy; or (iii) all permutations of two-drug therapy or all three drugs in combination. All groups contained at least 14 animals, and the control group received the drug vehicle. After 4 weeks, quantitative blood cultures were obtained and the number of bacteria in liver and spleen was quantitated. Moxifloxacin, ethambutol, and azithromycin were active as single agents in liver, spleen, and blood. Rifabutin showed inhibitory activity only in the blood. Two-drug combinations containing azithromycin were no more active than azithromycin alone. Similarly, the three-drug combination was not more active than azithromycin alone in the spleen. Rifabutin did not add to the activity of any other single agent or two-drug combination. Moxifloxacin at both concentrations in combination with ethambutol was significantly more active than each drug alone. |
| Author | Lowell S. Young Martin Wu Luiz E. Bermudez Clark B. Inderlied Mary Petrofsky Peter Kolonoski Priscilla Aralar |
| AuthorAffiliation | Kuzell Institute for Arthritis and Infectious Diseases, California Pacific Medical Center Research Institute, San Francisco, 1 and Children's Hospital of Los Angeles, University of Southern California, Los Angeles, 2 California |
| AuthorAffiliation_xml | – name: Kuzell Institute for Arthritis and Infectious Diseases, California Pacific Medical Center Research Institute, San Francisco, 1 and Children's Hospital of Los Angeles, University of Southern California, Los Angeles, 2 California |
| Author_xml | – sequence: 1 givenname: Luiz E surname: BERMUDEZ fullname: BERMUDEZ, Luiz E organization: Kuzell Institute for Arthritis and Infectious Diseases, California Pacific Medical Center Research Institute, San Francisco, United States – sequence: 2 givenname: Clark B surname: INDERLIED fullname: INDERLIED, Clark B organization: Children's Hospital of Los Angeles, University of Southern California, Los Angeles, California, United States – sequence: 3 givenname: Peter surname: KOLONOSKI fullname: KOLONOSKI, Peter organization: Kuzell Institute for Arthritis and Infectious Diseases, California Pacific Medical Center Research Institute, San Francisco, United States – sequence: 4 givenname: Mary surname: PETROFSKY fullname: PETROFSKY, Mary organization: Kuzell Institute for Arthritis and Infectious Diseases, California Pacific Medical Center Research Institute, San Francisco, United States – sequence: 5 givenname: Priscilla surname: ARALAR fullname: ARALAR, Priscilla organization: Children's Hospital of Los Angeles, University of Southern California, Los Angeles, California, United States – sequence: 6 givenname: Martin surname: WU fullname: WU, Martin organization: Kuzell Institute for Arthritis and Infectious Diseases, California Pacific Medical Center Research Institute, San Francisco, United States – sequence: 7 givenname: Lowell S surname: YOUNG fullname: YOUNG, Lowell S organization: Kuzell Institute for Arthritis and Infectious Diseases, California Pacific Medical Center Research Institute, San Francisco, United States |
| BackLink | http://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=912096$$DView record in Pascal Francis https://www.ncbi.nlm.nih.gov/pubmed/11120969$$D View this record in MEDLINE/PubMed |
| BookMark | eNqFkV1vFCEUhompsdvqT9CQmPSqMwLznXgz2VTdpI2JUW_JGQZ2aGagArPt-jf8w7IfWfXKGzgHnvecA-8FOjPWSIReU5JSyup3bbtM8yKlKaNVwhhLGSH0GVpQ0tRJWTTlGVoQUpZJXpP8HF14f09iXjTkBTqnsQRpymaBfrUi6I0OW2wVvrNPWo32CYQ2uNviVfByVBhMj-PB0k6dNhC0NfhRhwHfhAGmbg52vMZftIIYanO9x9ufEXB22u4qrQz-roOz-5t9sonxGrTxAd9the1ABOn0PGHYxPUleq5g9PLVcb9E3z7cfF1-Sm4_f1wt29sEioyFRNQgu6zKJFFZzliZ56IXZQNdoWQlVFXnVAjai5pWkmQ9LeKEed5kqlalVDG4RO8PdR_mbpK9kCY4GPmD0xO4Lbeg-b83Rg98bTe8IbFblF8d5c7-mKUPfNJeyHEEI-3sOa2qoswojWBxAIWz3jupTi0o4TszeTST5wWnPJrJo5l8Z2bUsYMO_MT4vZ2did_xX9Gbvx_1p9XR8gi8PQLgBYzKgRHan7hmj0UKH6hBr4dH7SSPQ3AAcWqZ_QYC7McD |
| CODEN | AACHAX |
| CitedBy_id | crossref_primary_10_1128_microbiolspec_TNMI7_0045_2017 crossref_primary_10_1038_srep29701 crossref_primary_10_1128_AAC_00320_12 crossref_primary_10_1016_j_ijantimicag_2004_09_018 crossref_primary_10_1016_j_micpath_2014_09_010 crossref_primary_10_1128_AAC_04841_14 crossref_primary_10_1128_AAC_00685_12 crossref_primary_10_1128_AAC_48_12_4907_4910_2004 crossref_primary_10_1016_j_ijantimicag_2010_12_014 crossref_primary_10_1371_journal_pone_0235797 crossref_primary_10_1080_10717540600739815 crossref_primary_10_1128_AAC_01303_06 crossref_primary_10_1016_j_antib_2010_01_010 crossref_primary_10_1517_14656560903369363 crossref_primary_10_1378_chest_07_0358 crossref_primary_10_1157_13073171 crossref_primary_10_1016_j_jtbi_2021_110949 crossref_primary_10_1128_AAC_00410_07 crossref_primary_10_1164_rccm_201204_0682OC crossref_primary_10_1128_AAC_49_6_2387_2398_2005 crossref_primary_10_1007_BF03256600 crossref_primary_10_1016_j_ijantimicag_2005_03_005 crossref_primary_10_1007_s10156_004_0316_4 crossref_primary_10_1128_AAC_01201_10 crossref_primary_10_1128_AAC_48_9_3556_3558_2004 crossref_primary_10_1128_AAC_01761_09 crossref_primary_10_1002_ppul_23825 crossref_primary_10_1053_jinf_2002_0970 crossref_primary_10_1128_AAC_02281_12 crossref_primary_10_1016_S0732_8893_03_00115_9 crossref_primary_10_1128_AAC_47_8_2685_2687_2003 crossref_primary_10_4236_gsc_2018_82014 crossref_primary_10_1016_S1579_2129_06_60432_1 crossref_primary_10_1097_01_SMJ_0000154311_60057_56 crossref_primary_10_1128_AAC_46_2_288_293_2002 crossref_primary_10_1093_jac_dki418 crossref_primary_10_1054_tube_2002_0373 crossref_primary_10_1016_j_jiac_2014_05_010 crossref_primary_10_3346_jkms_2020_35_e59 crossref_primary_10_1016_j_clinmicnews_2007_11_003 |
| Cites_doi | 10.1128/AAC.38.11.2521 10.1128/AAC.42.8.2060 10.1056/NEJM199105093241906 10.7326/0003-4819-121-12-199412150-00001 10.1128/AAC.42.1.180 10.1128/AAC.43.8.1870 10.1128/CMR.6.3.266 10.1128/AAC.38.8.1844 10.7326/0003-4819-105-2-184 10.1128/AAC.31.11.1697 10.1128/AAC.43.1.12 10.1164/ajrccm/137.1.149 10.1128/AAC.40.3.546 10.1128/AAC.39.6.1341 10.1128/AAC.43.1.85 10.1164/ajrccm/144.4.914 10.1128/AAC.38.12.2717 10.1128/AAC.42.8.2066 10.1093/jac/43.suppl_2.61 10.1016/0041-3879(91)90004-C 10.1128/AAC.39.4.976 10.1093/jac/43.suppl_2.69 10.1128/AAC.41.8.1818 |
| ContentType | Journal Article |
| Copyright | 2001 INIST-CNRS Copyright © 2001 American Society for Microbiology Copyright © 2001, American Society for Microbiology 2001 |
| Copyright_xml | – notice: 2001 INIST-CNRS – notice: Copyright © 2001 American Society for Microbiology – notice: Copyright © 2001, American Society for Microbiology 2001 |
| DBID | IQODW CGR CUY CVF ECM EIF NPM AAYXX CITATION 7QL 7T7 8FD C1K FR3 P64 5PM |
| DOI | 10.1128/AAC.45.1.217-222.2001 |
| DatabaseName | Pascal-Francis Medline MEDLINE MEDLINE (Ovid) MEDLINE MEDLINE PubMed CrossRef Bacteriology Abstracts (Microbiology B) Industrial and Applied Microbiology Abstracts (Microbiology A) Technology Research Database Environmental Sciences and Pollution Management Engineering Research Database Biotechnology and BioEngineering Abstracts PubMed Central (Full Participant titles) |
| DatabaseTitle | MEDLINE Medline Complete MEDLINE with Full Text PubMed MEDLINE (Ovid) CrossRef Engineering Research Database Technology Research Database Industrial and Applied Microbiology Abstracts (Microbiology A) Bacteriology Abstracts (Microbiology B) Biotechnology and BioEngineering Abstracts Environmental Sciences and Pollution Management |
| DatabaseTitleList | CrossRef Engineering Research Database MEDLINE |
| Database_xml | – sequence: 1 dbid: NPM name: PubMed url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed sourceTypes: Index Database – sequence: 2 dbid: EIF name: MEDLINE url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search sourceTypes: Index Database |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine Pharmacy, Therapeutics, & Pharmacology Biology |
| EISSN | 1098-6596 |
| EndPage | 222 |
| ExternalDocumentID | 10_1128_AAC_45_1_217_222_2001 0500 11120969 912096 aac_45_1_217 |
| Genre | Research Support, Non-U.S. Gov't Research Support, U.S. Gov't, P.H.S Journal Article |
| GrantInformation_xml | – fundername: PHS HHS grantid: N01A125140 |
| GroupedDBID | --- .55 .GJ 08R 0R~ 23M 2WC 39C 3O- 4.4 53G 5GY 5RE 5VS 6J9 AAPBV AAUGY ACGFO ADBBV AENEX AFMIJ AGNAY AI. ALMA_UNASSIGNED_HOLDINGS AOIJS BAWUL BTFSW C1A CS3 DIK E3Z EBS EJD F5P FRP GX1 H13 HH5 HYE HZ~ H~9 IQODW J5H K-O KQ8 L7B LSO MVM NEJ O9- OK1 P2P RHF RHI RNS RPM RSF TR2 UHB VH1 W2D W8F WH7 WHG WOQ X7M X7N XOL Y6R ZA5 ZGI ZXP ~A~ AGVNZ CGR CUY CVF ECM EIF NPM - 0R 55 ABFLS ADACO BXI GJ HZ AAYXX CITATION 7QL 7T7 8FD C1K FR3 P64 5PM |
| ID | FETCH-LOGICAL-a532t-c8aeb373e0f3422644cdc69ab5fe7cf7841cc1dc817e03d15fab4493f8f6ef493 |
| IEDL.DBID | RPM |
| ISSN | 0066-4804 |
| IngestDate | Tue Sep 17 21:22:35 EDT 2024 Fri Oct 25 09:45:17 EDT 2024 Thu Sep 12 16:51:26 EDT 2024 Tue Dec 28 13:59:10 EST 2021 Sat Sep 28 07:35:07 EDT 2024 Sun Oct 22 16:09:33 EDT 2023 Wed May 18 15:26:58 EDT 2016 |
| IsDoiOpenAccess | false |
| IsOpenAccess | true |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 1 |
| Keywords | Drug combination Azithromycin Oral administration Mycobacterium avium Moxifloxacin In vitro Macrolide Biological activity Rifabutin In vivo Antibiotic Fluoroquinolone derivatives Mycobacteriales Mycobacteriaceae Bacteria Ethambutol Actinomycetes Drug interaction Antibacterial agent Quinolone derivatives |
| Language | English |
| License | CC BY 4.0 |
| LinkModel | DirectLink |
| MergedId | FETCHMERGED-LOGICAL-a532t-c8aeb373e0f3422644cdc69ab5fe7cf7841cc1dc817e03d15fab4493f8f6ef493 |
| Notes | ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-Feature-1 content type line 23 Corresponding author. Mailing address: Kuzell Institute, 2200 Webster St., Suite 305, San Francisco, CA 94115. |
| OpenAccessLink | https://doi.org/10.1128/aac.45.1.217-222.2001 |
| PMID | 11120969 |
| PQID | 17756311 |
| PQPubID | 23462 |
| PageCount | 6 |
| ParticipantIDs | pubmedcentral_primary_oai_pubmedcentral_nih_gov_90264 highwire_asm_aac_45_1_217 asm2_journals_10_1128_AAC_45_1_217_222_2001 crossref_primary_10_1128_AAC_45_1_217_222_2001 pubmed_primary_11120969 pascalfrancis_primary_912096 proquest_miscellaneous_17756311 |
| PublicationCentury | 2000 |
| PublicationDate | 20010101 2001 2001-Jan 2001-01-00 |
| PublicationDateYYYYMMDD | 2001-01-01 |
| PublicationDate_xml | – month: 01 year: 2001 text: 20010101 day: 01 |
| PublicationDecade | 2000 |
| PublicationPlace | Washington, DC |
| PublicationPlace_xml | – name: Washington, DC – name: United States |
| PublicationTitle | Antimicrobial Agents and Chemotherapy |
| PublicationTitleAbbrev | Antimicrob. Agents Chemother |
| PublicationTitleAlternate | Antimicrob Agents Chemother |
| PublicationYear | 2001 |
| Publisher | American Society for Microbiology |
| Publisher_xml | – name: American Society for Microbiology |
| References | 7872741 - Antimicrob Agents Chemother. 1994 Nov;38(11):2521-9 10428905 - Antimicrob Agents Chemother. 1999 Aug;43(8):1870-4 7978715 - Ann Intern Med. 1994 Dec 15;121(12):905-11 8851568 - Antimicrob Agents Chemother. 1996 Mar;40(3):546-51 2017230 - N Engl J Med. 1991 May 9;324(19):1332-8 1928970 - Am Rev Respir Dis. 1991 Oct;144(4):914-6 7786006 - Antimicrob Agents Chemother. 1995 Apr;39(4):976-8 10382877 - J Antimicrob Chemother. 1999 May;43 Suppl B:61-7 8358707 - Clin Microbiol Rev. 1993 Jul;6(3):266-310 7574527 - Antimicrob Agents Chemother. 1995 Jun;39(6):1341-4 4957125 - Cancer Chemother Rep. 1966 May;50(4):219-44 1663283 - Tubercle. 1991 Sep;72(3):181-6 9869570 - Antimicrob Agents Chemother. 1999 Jan;43(1):85-9 9687408 - Antimicrob Agents Chemother. 1998 Aug;42(8):2066-9 3729201 - Ann Intern Med. 1986 Aug;105(2):184-8 10382878 - J Antimicrob Chemother. 1999 May;43 Suppl B:69-76 9449283 - Antimicrob Agents Chemother. 1998 Jan;42(1):180-3 9869557 - Antimicrob Agents Chemother. 1999 Jan;43(1):12-5 7695252 - Antimicrob Agents Chemother. 1994 Dec;38(12):2717-21 3337456 - Am Rev Respir Dis. 1988 Jan;137(1):149-52 3124736 - Antimicrob Agents Chemother. 1987 Nov;31(11):1697-702 9257770 - Antimicrob Agents Chemother. 1997 Aug;41(8):1818-24 9687407 - Antimicrob Agents Chemother. 1998 Aug;42(8):2060-5 7986018 - Antimicrob Agents Chemother. 1994 Aug;38(8):1844-8 Contreras, M. A., Cheung, O. T., Sanders, D. E., Goldstein, R. S. (B7) 1988; 137 Stass, H., Dalhoff, A., Kubitza, D., Schuhly, U. (B24) 1998; 42 Hawkins, C. C., Gold, J. W., Whimbey, E., Kiehn, T. E., Brannon, P., Cammarata, R., Brown, A. E., Armstrong, D. (B10) 1986; 105 Ji, B., Truffot-Pernot, C., Grosset, J. (B18) 1991; 72 Rastogi, N., Labrousse, V., Bryskier, A. (B21) 1995; 39 Ji, B., Lounis, N., Truffot-Pernot, C., Grosset, J. (B17) 1995; 39 Inderlied, C. B., Kemper, C. A., Bermudez, L. E. (B12) 1993; 6 Siefert, H. M., Kohlsdorfer, C., Steinke, W., Witt, A. (B23) 1999; 43 (Suppl. B) Bermudez, L. E., Inderlied, C. B., Kolonoski, P., Petrofsky, M., Young, L. S. (B1) 1994; 38 Bermudez, L. E., Kolonoski, P., Young, L. S., Inderlied, C. B. (B4) 1994; 38 Pascual, A., Garcia, I., Ballesta, S., Perea, E. J. (B20) 1999; 43 Fass, R. J. (B8) 1997; 41 Chaisson, R. E., Benson, C. A., Dube, M. P., Heifets, L. B., Korvick, J. A., Elkin, S., Smith, T., Craft, J. C., Sattler, F. R. (B6) 1994; 121 Freireich, E. J., Gehan, E. A., Rall, D. P., Schmidt, L. H., Skipper, H. E. (B9) 1996; 50 Miyazaki, E., Miyazaki, M., Chen, J. M., Chaisson, R. E., Bishai, W. R. (B19) 1999; 43 Bermudez, L. E., Inderlied, C. B., Kolonoski, P., Wu, M., Barbara-Burnham, L., Young, L. S. (B2) 1996; 40 Ji, B., Lounis, N., Truffot-Pernot, C., Grosset, J. (B16) 1994; 38 Bermudez, L. E., Kolonoski, P., Wu, M., Aralar, P. A., Inderlied, C. B., Young, L. S. (B3) 1999; 43 Inderlied, C. B., Young, L. S., Yamada, J. K. (B13) 1987; 31 Bermudez, L. E., Petrofsky, M., Kolonoski, P., Young, L. S. (B5) 1998; 42 Ji, B., Lounis, N., Maslo, C., Truffot-Pernot, C., Bonnafous, P., Grosset, J. (B15) 1998; 42 Siefert, H. M., Domdey-Bette, A., Henninger, K., Hucke, F., Kohlsdorfer, C., Stass, H. H. (B22) 1999; 43 (Suppl. B) Horsburgh, C. R. (B11) 1991; 324 Iseman, M. D., Buschman, D. L., Ackerson, L. M. (B14) 1991; 144 e_1_3_2_9_2 e_1_3_2_16_2 e_1_3_2_7_2 e_1_3_2_17_2 e_1_3_2_6_2 e_1_3_2_18_2 Hawkins C. C. (e_1_3_2_11_2) 1986; 105 Siefert H. M. (e_1_3_2_24_2) 1999; 43 Iseman M. D. (e_1_3_2_15_2) 1991; 144 e_1_3_2_20_2 Freireich E. J. (e_1_3_2_10_2) 1996; 50 e_1_3_2_21_2 e_1_3_2_5_2 e_1_3_2_22_2 e_1_3_2_4_2 e_1_3_2_12_2 e_1_3_2_3_2 e_1_3_2_13_2 Siefert H. M. (e_1_3_2_23_2) 1999; 43 e_1_3_2_2_2 e_1_3_2_14_2 e_1_3_2_25_2 Ji B. (e_1_3_2_19_2) 1991; 72 Contreras M. A. (e_1_3_2_8_2) 1988; 137 |
| References_xml | – volume: 31 start-page: 1697 year: 1987 end-page: 1702 ident: B13 article-title: Determination of in vitro susceptibility of Mycobacterium avium complex isolates to antimycobacterial agents by various methods. publication-title: Antimicrob. Agents Chemother. contributor: fullname: Yamada, J. K. – volume: 40 start-page: 546 year: 1996 end-page: 551 ident: B2 article-title: Activities of BAY Y 3118, levofloxacin, and ofloxacin alone or in combination with ethambutol against Mycobacterium avium complex in vitro, in human macrophages, and in beige mice. publication-title: Antimicrob. Agents Chemother. contributor: fullname: Young, L. S. – volume: 137 start-page: 149 year: 1988 end-page: 152 ident: B7 article-title: Pulmonary infection with nontuberculous mycobacteria. publication-title: Am. Rev. Respir. Dis. contributor: fullname: Goldstein, R. S. – volume: 39 start-page: 1341 year: 1995 end-page: 1344 ident: B17 article-title: In vitro and in vivo activities of levofloxacin against Mycobacterium tuberculosis. publication-title: Antimicrob. Agents Chemother. contributor: fullname: Grosset, J. – volume: 41 start-page: 1818 year: 1997 end-page: 1824 ident: B8 article-title: In vitro activity of Bay 12-8039, a new 8-methoxyquinolone. publication-title: Antimicrob. Agents Chemother. contributor: fullname: Fass, R. J. – volume: 72 start-page: 181 year: 1991 end-page: 186 ident: B18 article-title: In vitro and in vivo activities of sparfloxacin (AT-4140) against Mycobacterium tuberculosis. publication-title: Tubercle contributor: fullname: Grosset, J. – volume: 42 start-page: 2066 year: 1998 end-page: 2069 ident: B15 article-title: In vitro and in vivo activities of moxifloxacin and clinafloxacin against Mycobacterium tuberculosis. publication-title: Antimicrob. Agents Chemother. contributor: fullname: Grosset, J. – volume: 43 start-page: 12 year: 1999 end-page: 15 ident: B20 article-title: Uptake and intracellular activity of moxifloxacin in human neutrophils and tissue-cultured epithelial cells. publication-title: Antimicrob. Agents Chemother. contributor: fullname: Perea, E. J. – volume: 39 start-page: 976 year: 1995 end-page: 978 ident: B21 article-title: Intracellular activities of roxithromycin used alone and in association with other drugs against Mycobacterium avium complex in human macrophages. publication-title: Antimicrob. Agents Chemother. contributor: fullname: Bryskier, A. – volume: 105 start-page: 184 year: 1986 end-page: 188 ident: B10 article-title: Mycobacterium avium complex infections in patients with the acquired immunodeficiency syndrome. publication-title: Ann. Intern. Med. contributor: fullname: Armstrong, D. – volume: 50 start-page: 219 year: 1996 end-page: 244 ident: B9 article-title: Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey and man. publication-title: Cancer Chemother. Rep. contributor: fullname: Skipper, H. E. – volume: 42 start-page: 180 year: 1998 end-page: 183 ident: B5 article-title: Emergence of Mycobacterium avium populations resistant to macrolides during experimental chemotherapy. publication-title: Antimicrob. Agents Chemother. contributor: fullname: Young, L. S. – volume: 43 start-page: 1870 year: 1999 end-page: 1874 ident: B3 article-title: Mefloquine is active in vitro and in vivo against Mycobacterium avium complex. publication-title: Antimicrob. Agents Chemother. contributor: fullname: Young, L. S. – volume: 43 start-page: 85 year: 1999 end-page: 89 ident: B19 article-title: Moxifloxacin (BAY12–8039), a new 8-methoxyquinolone, is active in a mouse model of tuberculosis. publication-title: Antimicrob. Agents Chemother. contributor: fullname: Bishai, W. R. – volume: 43 (Suppl. B) start-page: 69 year: 1999 end-page: 76 ident: B22 article-title: Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: a comparison in humans and other mammalian species. publication-title: J. Antimicrob. Chemother. contributor: fullname: Stass, H. H. – volume: 6 start-page: 266 year: 1993 end-page: 310 ident: B12 article-title: The Mycobacterium avium complex. publication-title: Clin. Microbiol. Rev. contributor: fullname: Bermudez, L. E. – volume: 42 start-page: 2060 year: 1998 end-page: 2065 ident: B24 article-title: Pharmacokinetics, safety, and tolerability of ascending single doses of moxifloxacin, a new 8-methoxy quinolone, administered to healthy subjects. publication-title: Antimicrob. Agents Chemother. contributor: fullname: Schuhly, U. – volume: 38 start-page: 1844 year: 1994 end-page: 1848 ident: B4 article-title: Activity of KRM 1648 alone or in combination with ethambutol or clarithromycin against Mycobacterium avium in beige mouse model of disseminated infection. publication-title: Antimicrob. Agents Chemother. contributor: fullname: Inderlied, C. B. – volume: 38 start-page: 2521 year: 1994 end-page: 2529 ident: B16 article-title: Effectiveness of various antimicrobial agents against Mycobacterium avium complex in the beige mouse model. publication-title: Antimicrob. Agents Chemother. contributor: fullname: Grosset, J. – volume: 43 (Suppl. B) start-page: 61 year: 1999 end-page: 67 ident: B23 article-title: Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: tissue distribution in male rats. publication-title: J. Antimicrob. Chemother. contributor: fullname: Witt, A. – volume: 38 start-page: 2717 year: 1994 end-page: 2721 ident: B1 article-title: Clarithromycin, dapsone, and a combination of both used to treat or prevent disseminated Mycobacterium avium infection in beige mice. publication-title: Antimicrob. Agents Chemother. contributor: fullname: Young, L. S. – volume: 144 start-page: 914 year: 1991 end-page: 916 ident: B14 article-title: Pectus excavatum and scoliosis. Thoracic anomalies associated with pulmonary disease caused by Mycobacterium avium complex. publication-title: Am. Rev. Respir. Dis. contributor: fullname: Ackerson, L. M. – volume: 121 start-page: 905 year: 1994 end-page: 911 ident: B6 article-title: Clarithromycin therapy for bacteremic Mycobacterium avium complex disease. A randomized, double-blind, dose-ranging study in patients with AIDS. AIDS Clinical Trials Group Protocol 157 Study Team. publication-title: Ann. Intern. Med. contributor: fullname: Sattler, F. R. – volume: 324 start-page: 1332 year: 1991 end-page: 1338 ident: B11 article-title: Mycobacterium avium complex infection in the acquired immunodeficiency syndrome. publication-title: N. Engl. J. Med. contributor: fullname: Horsburgh, C. R. – ident: e_1_3_2_17_2 doi: 10.1128/AAC.38.11.2521 – ident: e_1_3_2_25_2 doi: 10.1128/AAC.42.8.2060 – ident: e_1_3_2_12_2 doi: 10.1056/NEJM199105093241906 – ident: e_1_3_2_7_2 doi: 10.7326/0003-4819-121-12-199412150-00001 – ident: e_1_3_2_6_2 doi: 10.1128/AAC.42.1.180 – ident: e_1_3_2_4_2 doi: 10.1128/AAC.43.8.1870 – ident: e_1_3_2_13_2 doi: 10.1128/CMR.6.3.266 – ident: e_1_3_2_5_2 doi: 10.1128/AAC.38.8.1844 – volume: 50 start-page: 219 year: 1996 ident: e_1_3_2_10_2 article-title: Quantitative comparison of toxicity of anticancer agents in mouse, rat, hamster, dog, monkey and man. publication-title: Cancer Chemother. Rep. contributor: fullname: Freireich E. J. – volume: 105 start-page: 184 year: 1986 ident: e_1_3_2_11_2 article-title: Mycobacterium avium complex infections in patients with the acquired immunodeficiency syndrome. publication-title: Ann. Intern. Med. doi: 10.7326/0003-4819-105-2-184 contributor: fullname: Hawkins C. C. – ident: e_1_3_2_14_2 doi: 10.1128/AAC.31.11.1697 – ident: e_1_3_2_21_2 doi: 10.1128/AAC.43.1.12 – volume: 137 start-page: 149 year: 1988 ident: e_1_3_2_8_2 article-title: Pulmonary infection with nontuberculous mycobacteria. publication-title: Am. Rev. Respir. Dis. doi: 10.1164/ajrccm/137.1.149 contributor: fullname: Contreras M. A. – ident: e_1_3_2_3_2 doi: 10.1128/AAC.40.3.546 – ident: e_1_3_2_18_2 doi: 10.1128/AAC.39.6.1341 – ident: e_1_3_2_20_2 doi: 10.1128/AAC.43.1.85 – volume: 144 start-page: 914 year: 1991 ident: e_1_3_2_15_2 article-title: Pectus excavatum and scoliosis. Thoracic anomalies associated with pulmonary disease caused by Mycobacterium avium complex. publication-title: Am. Rev. Respir. Dis. doi: 10.1164/ajrccm/144.4.914 contributor: fullname: Iseman M. D. – ident: e_1_3_2_2_2 doi: 10.1128/AAC.38.12.2717 – ident: e_1_3_2_16_2 doi: 10.1128/AAC.42.8.2066 – volume: 43 start-page: 61 year: 1999 ident: e_1_3_2_24_2 article-title: Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: tissue distribution in male rats. publication-title: J. Antimicrob. Chemother. doi: 10.1093/jac/43.suppl_2.61 contributor: fullname: Siefert H. M. – volume: 72 start-page: 181 year: 1991 ident: e_1_3_2_19_2 article-title: In vitro and in vivo activities of sparfloxacin (AT-4140) against Mycobacterium tuberculosis. publication-title: Tubercle doi: 10.1016/0041-3879(91)90004-C contributor: fullname: Ji B. – ident: e_1_3_2_22_2 doi: 10.1128/AAC.39.4.976 – volume: 43 start-page: 69 year: 1999 ident: e_1_3_2_23_2 article-title: Pharmacokinetics of the 8-methoxyquinolone, moxifloxacin: a comparison in humans and other mammalian species. publication-title: J. Antimicrob. Chemother. doi: 10.1093/jac/43.suppl_2.69 contributor: fullname: Siefert H. M. – ident: e_1_3_2_9_2 doi: 10.1128/AAC.41.8.1818 |
| SSID | ssj0006590 |
| Score | 1.9089967 |
| Snippet | Classifications
Services
AAC
Citing Articles
Google Scholar
PubMed
Related Content
Social Bookmarking
CiteULike
Delicious
Digg
Facebook
Google+
Mendeley
Reddit... Moxifloxacin activity against Mycobacterium avium complex (MAC) was evaluated in vitro against 25 strains. The MIC was determined to range from 0.125 to 2.0... Moxifloxacin activity against Mycobacterium aviumcomplex (MAC) was evaluated in vitro against 25 strains. The MIC was determined to range from 0.125 to 2.0... ABSTRACT Moxifloxacin activity against Mycobacterium avium complex (MAC) was evaluated in vitro against 25 strains. The MIC was determined to range from 0.125... Moxifloxacin activity against Mycobacterium avium complex (MAC) was evaluated in vitro against 25 strains. The MIC was determined to range from 0.125 to 2.0 mu... Moxifloxacin activity against Mycobacterium avium complex (MAC) was evaluated in vitro against 25 strains. The MIC was determined to range from 0.125 to 2.0... |
| SourceID | pubmedcentral proquest crossref asm2 pubmed pascalfrancis highwire |
| SourceType | Open Access Repository Aggregation Database Index Database Publisher |
| StartPage | 217 |
| SubjectTerms | Animals Anti-Bacterial Agents Anti-Bacterial Agents - pharmacology Anti-Bacterial Agents - therapeutic use Anti-Infective Agents Anti-Infective Agents - pharmacology Anti-Infective Agents - therapeutic use Antibacterial agents Antibiotics. Antiinfectious agents. Antiparasitic agents Antitubercular Agents Antitubercular Agents - pharmacology Antitubercular Agents - therapeutic use Aza Compounds Azithromycin Azithromycin - pharmacology Azithromycin - therapeutic use Biological and medical sciences Drug Interactions Drug Therapy, Combination Ethambutol Ethambutol - pharmacology Ethambutol - therapeutic use Experimental Therapeutics Female Fluoroquinolones Macrophages - drug effects Macrophages - microbiology Medical sciences Mice Mice, Inbred C57BL Microbial Sensitivity Tests Moxifloxacin Mycobacterium avium Mycobacterium avium Complex Mycobacterium avium Complex - drug effects Mycobacterium avium-intracellulare Infection Mycobacterium avium-intracellulare Infection - drug therapy Mycobacterium avium-intracellulare Infection - microbiology Pharmacology. Drug treatments Quinolines Rifabutin Rifabutin - pharmacology Rifabutin - therapeutic use |
| Title | Activity of Moxifloxacin by Itself and in Combination with Ethambutol, Rifabutin, and Azithromycin In Vitro and In Vivo against Mycobacterium avium |
| URI | http://aac.asm.org/content/45/1/217.abstract https://www.ncbi.nlm.nih.gov/pubmed/11120969 https://journals.asm.org/doi/10.1128/AAC.45.1.217-222.2001 https://search.proquest.com/docview/17756311 https://pubmed.ncbi.nlm.nih.gov/PMC90264 |
| Volume | 45 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLbYJBAvCMotMIYf0F5o2jixc3msqk0bqKigDe3Nchx7i9Qk05JOC3-DP8yxk7QUISEhRZGTOI4Tf-f4nPhcEPqgZBzIVGYu8YXn0iz13RSkAjf0qWCSZTqwtjmLL-HpBf10yS57P-66N6ssZZpPylUxKfNra1t5U8jpYCc2XS7mCSgOdLqH9gCeg4LeM9-Qdb9VYCZ1aezR3mkHuPB0NptPKJuAUgiMGaZFoxzaRDHE-I9ai2dRF_7uBDUEDTY2k6KGz6a7fBd_E0j_tKv8baI6eYqe9BImnnVv8gw9UOUIPexyTrYj9GjRr6aP0NGyi1vdjvH51g2rHuMjvNxGtG6fo58z2SWZwJXGi-o-16vqXkAjOG3xWVOrlcaizDCcAP4CurYdbmz-8eLj5loU6bqpVmP8LdfCpNcqx7b67EdusjQUrWnprMTf8-a2slfswR2Ur0QO8itetBL4jo0rvS6wuIP9C3Rxcnw-P3X7bA6uYIHfuDIWoLhHgfJ0YN13qcxkmIiUaWViI8WUSEkyGZNIeUFGGPSI0iTQsQ6VhsJLtF9WpXqNMJWSxilRUsSCBp5MNCORzjJfR0mqPOagj2YkeU-ONbeajh9zgACnjBMOEOAAAZOEkzhoMgw4v-lCfPzrBmeABYfncCHkppKDDnZwsmkxsSBz0PsBNhzo2CzOiFJVa-hiFLEwIND4qw5E2770-HQQ24HXpoKJEL57BQjHRgq3hPLmP-97ix53BndmO0D7ze1avQMJrEkP0d7nr_GhpbxfEd8wUA |
| link.rule.ids | 230,315,730,783,787,888,4031,27935,27936,27937,53804,53806 |
| linkProvider | National Library of Medicine |
| linkToHtml | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1bb9MwFLZgiMsLgnILDOYHtBeaNhc7l8eq2tTCMlWoQ3uzHMdmkZpkWtJp5W_whzl2kpYiJCSkKEriS5z4O8fnJOeC0EcpIl-kIrNdjzs2yVLPTkEqsAOPcCpopnxjm5OcB7ML8vmSXnZ-3HVnVlmKNB-Vq2JU5lfGtvK6EOPeTmy8SKYxKA5kfB89AGp1SK-id-w3oO2HFVhLbQLFndsO8OHxZDIdEToCtRBYMyyMWj00qWJc7UFqbJ55XXj7S1QfNlhbTfIaXpxqM178TST907Lyt6Xq9Bl62smYeNI-y3N0T5YD9LDNOrkZoEdJ9z99gI4XbeTqzRAvd45Y9RAf48UupvXmBfo5EW2aCVwpnFR3uVpVdxw6wekGz5tarhTmZYbhAnAY0LbNhGP9lRefNFe8SNdNtRrir7niOsFWOTTVJz9ynaeh2Oie5iX-ljc3lSkxJ7dw_J3nIMHiZCOA85jI0usC81vYv0QXpyfL6czu8jnYnPpeY4uIg-oe-tJRvnHgJSITQcxTqqSOjhQRVwg3E5EbSsfPXAojIiT2VaQCqeDgFTooq1K-QZgIQaLUlYJHnPiOiBV1Q5VlngrjVDrUQp_0TLKOIGtmdB0vYgABRihzGUCAAQR0Gk7XQqN-wtl1G-TjXw2sHhYM7sM4F9tKFjrcw8m2x9iAzEJHPWwYULL-PcNLWa1hiGFIA9-Fzl-3INqNpcOnhegevLYVdIzw_RIgHRMr3JDK2_9sd4Qez5bJGTubn395h5605nd6O0QHzc1avgd5rEk_GPr7BQhfMrE |
| linkToPdf | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELdgiIkXBOUrMJgf0F5o2nzY-XisyqoV6FShDe3NchybRWqSakmnhX-Df5izk7QUISEhRZGT2I4T_-58Z5_vEHovReSLRKS263HHJmni2QlIBXbgEU4FTZVvbHMW58HZJfl0Ra-6qYuqM6ssRJKNilU-KrJrY1u5zsW4txMbLxfTGBQHMl6nanwfPQCKdYJeTe9YcEDbyRUYT20SOaTbugO8eDyZTEeEjkA1BPYMg6NWEU24GFfvIjV2z7zKvf1hqncdrC0neQU_T7VRL_4mlv5pXfnbcDV7gh53ciaetN_zFN2TxQA9bCNPNgN0uOjW1AfoZNl6r26G-GK3Gasa4hO83Pm1bp6hnxPRhprApcKL8i5Tq_KOQyU4afC8ruRKYV6kGG4AlwGN23Q61jO9-LS-5nmyqcvVEH_NFNdBtoqhyT75kelYDXmja5oX-FtW35Tmibm4hfR3noEUixeNAO5jvEtvcsxv4fwcXc5OL6ZndhfTwebU92pbRBzU99CXjvLNJl4iUhHEPKFKag9JEXGFcFMRuaF0_NSl0CJCYl9FKpAKEi_QQVEW8hXCRAgSJa4UPOLEd0SsqBuqNPVUGCfSoRb6oHuSdURZMaPveBEDCDBCmcsAAgwgoENxuhYa9R3O1q2jj38VsHpYMHgP41xsM1noaA8n2xpjAzILHfewYUDNeomGF7LcQBPDkAa-C5W_bEG0a0uHTwvRPXhtM2g_4ftPgHyMv3BDLq__s9wxOlx-nLEv8_PPb9Cj1gJPH0fooL7ZyLcgktXJO0N-vwBmpjPE |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Activity+of+moxifloxacin+by+itself+and+in+combination+with+ethambutol%2C+rifabutin%2C+and+azithromycin+in+vitro+and+in+vivo+against+Mycobacterium+avium&rft.jtitle=Antimicrobial+agents+and+chemotherapy&rft.au=BERMUDEZ%2C+Luiz+E&rft.au=INDERLIED%2C+Clark+B&rft.au=KOLONOSKI%2C+Peter&rft.au=PETROFSKY%2C+Mary&rft.date=2001&rft.pub=American+Society+for+Microbiology&rft.issn=0066-4804&rft.eissn=1098-6596&rft.volume=45&rft.issue=1&rft.spage=217&rft.epage=222&rft_id=info:doi/10.1128%2FAAC.45.1.217-222.2001&rft.externalDBID=n%2Fa&rft.externalDocID=912096 |
| thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0066-4804&client=summon |
| thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0066-4804&client=summon |
| thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0066-4804&client=summon |